IQVIA™ Real-World Insights Bibliography

Assessment of the economic value of the INTERCEPT Blood System in Belgium.
Author(s): Moeremans K; Annemans L.
Affiliations(s): 
Publication(s):  Transfusion Medicine, 2006; 16:17-30
Document Type(s): Manuscript in preparation,
Countries: Belgium,
C:
Y:
Health economics,
2006
  L:
A:
English
  Add to report
 
 
Assesment of the economic value of the INTERCEPT blood system in Belgium.
Author(s): Moeremans K, Warie H, Annemans L
Affiliations(s): 
Publication(s):  Transfus Med.; 16:17-30
Document Type(s): Manuscript in preparation,
Countries: Belgium,
C:
Y:
Hematology,
2006
  L:
A:
English
  Add to report
 
 
A cost-consequence analysis of darbepoetin alfa administered every 3 weeks (Q3W_DA) compared to weekly epoetin alfa (QW_EA) or epoetin beta (WQ_EB) in patients with chemotherapy-induced anemia (CIA): A retrospective study.
Author(s): Van Bellinghen LA, Demarteau N, Annemans, Bracco A
Affiliations(s): 
Publication(s):  ISPOR 9th Annual European Congress, 2006, October 29-31, Copenhagen, Denmark
Document Type(s): Poster,
Countries: Belgium,
C:
Y:
Oncology,
2006
  L:
A:
English
Cost consequence,
  Add to report
 
 
An update: Health economics of managing multiple myeloma
Author(s): K Moeremans, L Annemans.
Affiliations(s): 
Publication(s):  European Journal of Cancer, 2006; 42(11):1684-96
Document Type(s): Manuscript in preparation,
Countries: Belgium,
C:
Y:
Oncology,
2006
  L:
A:
English
  Add to report
 
 
Treatment of actinic keratosis (AK) and basal cell carcinoma (BCC) with Metvix® (MAL-PDT) in real life practice: a cost of illness and model validation study.
Author(s): Caekelbergh K1, Annemans L1
Affiliations(s): 1 IMS Health, Brussels, Belgium
Publication(s):  ISPOR 9th Annual European Congress, 2006, October 29-31, Copenhagen, Denmark
Document Type(s): Poster,
Countries: Belgium,
C:
Y:
Oncology,
2006
  L:
A:
English
Cost of illness,
  Add to report
 
 
First Page Previous Page  15 of 15